-+ 0.00%
-+ 0.00%
-+ 0.00%

Pfizer Announced Saturday, HYMPAVZI Reduced Bleeds By 93% Vs On-Demand Treatment In Adults And Adolescents With Hemophilia A Or B With Inhibitors

Benzinga·12/07/2025 23:13:55
Listen to the news

Pfizer Inc. (NYSE:PFE) presented results from the Phase 3 BASIS study (NCT03938792) evaluating HYMPAVZI® (marstacimab) for adults and adolescents living with hemophilia A or B with inhibitors. The results demonstrated the superiority of HYMPAVZI in improving key bleeding outcomes compared to on-demand (OD) treatment with bypassing agents. HYMPAVZI was administered with a straightforward, once-weekly subcutaneous injection requiring minimal preparation and no treatment-related lab monitoring.

HYMPAVZI® (marstacimab) Reduced Bleeds by 93% Compared to On-Demand Treatment in Adults and Adolescents with Hemophilia A or B with Inhibitors

  • Findings from the Phase 3 study were presented at the 67th American Society of Hematology Annual Meeting and Exposition and published in Blood